Pancreatic cancer is the seventh leading cause of cancer death worldwide. There were approximately 495,800 new cases of pancreatic cancer and 466,000 deaths from the disease worldwide in 2020. The American Cancer Society estimates 64,050 people will be diagnosed with pancreatic cancer and 50,550 people will die of pancreatic cancer in 2023. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S. by 2030. We have initiated and are recruiting for a Phase 1b/2 clinical trial of batiraxcept in patients with pancreatic adenocarcinoma (NCT04983407).